Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Syneos Health SYNH recently entered into a definitive agreement to be acquired by a private investment consortium in an all-cash transaction of approximately $7.1 billion. The consortium of private investment firm affiliates includes Elliott Investment Management, Patient Square Capital and Veritas Capital.
MAY 2023
Depends on broker but yes is the answer.
Need to remember this ?
Our new COO
Dr Sargent held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH)
Syneos Health was taken private and bought out for 7 billion dollars in May 2023
Precision Dosing Tool / Application for the treatment of Prostate Cancer currently under Trial and supported by UKRI
The FDA - From the regulatory perspective, AI/ML-based solutions can be considered medical devices (i.e., Software as Medical Device, SaMD)
Bit worrying that someone can be so angry and obsessed…
I give zero about there opinion anyway
The grant is for an ongoing product that needs. Validation which is industry norm.
The article was from yesterday!!!
And the fact it’s a continuation on the Dosing Application that all Grant Applications state it’s a route to commercialisation
That’s my understanding as the funding will be drip fed across a period of time.
As per the article published yesterday they list all companies being funded PYC being one of then
Wow your angry….
Anyway thanks for the post…kinda irrelevant to the topic of the link about PYC getting a chunk of the £10million as a Grant…
It’s ready to jump - breaks to an 2.60 is pretty much next leg up
I’m expecting 2.80/3.00 before any news with the amount of shares in issues doesn’t take a lot to move this.
MC is so undervalued.
Merck Deal knock knock ???
Most the buys last week were recorded as sell.
Imo - I believe we will have news / contract(s) pre Christmas
Thanks Ralphie - i also see Ankyra sign a supply agreement with Regeneron 90 Billion MC
Surely PYC working on the likes of ANK 101 across 2 projects with the data being provided to big hitters in the industry can only be a good thing lol - just wish the company would shout about it alittle more. PR after all....
I see Ankyra and Merck have signed a collaboration and supply agreement for ANK 101 (Well October - I missed this)
PYC worked on ANK101 with Ankyra and were given two contracts !!!
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting 16th November 2023
Was this what PYC was working on ? The module was never disclosed? I
Not Sure... obviously we have a work relationship with DosemeRx and our software is already integrated into its platform. (This can be seen on the RNS feeds)
Obvs Doseme got sold buy TabulaRasa earlier on in the year... Doseme seems over the past 6 weeks are so publishing a lot of new contracts, integration and being very vocal about the product...
Maybe we are due an update...?
More News
DoseMe Adds Cefepime to Its Model-informed Precision Dosing Platform
HITRUST CSF certified Bayesian dosing platform standardizes dosing mechanisms to optimize antibiotic efficacy in critically ill patients
December 4, 2023
DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the availability of its Cefepime model. This model will offer pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for Cefepime in critically ill patients, including those with unstable renal function, a common challenge faced by clinicians taking care of these complex patients.
Mark Scheetz is a professor at Midwestern University, Chicago College of Pharmacy and holds a joint appointment at Department of Pharmacology, College of Graduate Studies and is the Director of Pharmacometric Center of Excellence at Midwestern University. His research continues to highlight three keys to infectious disease monitoring – real time beta lactam monitoring, therapeutic drug monitoring and precision dosing. “Similar to many beta lactam treatments, Cefepime displays a large amount of variability between patients and having DoseMeRx enables precision dosing,” stated Scheetz. “Pharmacists know when patients’ clearances are changing and they know that creatinine clearance does not capture the drug clearance. It is going to become more prevalent that all drugs need to be monitored.”
The fourth-generation cephalosporin antibiotic is used in the treatment and management of gram-positive and gram-negative bacterial infections. Its most common uses are for pneumonia, skin and soft-tissue infections, complicated intra-abdominal infections, and neutropenic fever. Cefepime is associate with a higher risk of neurotoxicity, particularly in renal dysfunction, as evidenced by a study by Boschung-Pasquier, L. et al. where neurotoxic symptoms were observed in 54% of patients with eGFR 90 mL/min/1.73m2). Utilizing model-informed precision dosing (MIPD) software could minimize this risk.
“As the awareness around suboptimal dosing as a major factor in patient risk increases, DoseMe is at the forefront of innovation,” stated Dr. Sharmeen Roy, PharmD, BCPS, Chief Strategy & Science Officer. “The platform combines smart technology with science leveraging clinically-validated PK/PD models and now pharmacists at healthcare organizations around the globe can dose Cefepime with confidence.”
Therapeutic drug monitoring (TDM) and model-informed precision dosing (MIPD) have evolved as important tools to inform rational dosing of antibiotics in individual patients with infections. In particular, critically ill patients are at the highest risk and often suffer from infections caused by less susceptible bacteria. Greater recognition of the benefits of Model-informed
UTMB Taps DoseMe’s Genetic Biomarker Capabilities for Precision Dosing
Health Science Center to Launch Antibiotic Models for Improved Patient Care; Future Deployment of Wide Range of Models Approved for Rollout
December 6, 2023
DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring and creators of DoseMeRx and DoseMe Analytics, today announced University of Texas Medical Branch (UTMB) will utilize the DoseMe platform to advance its genetic biomarker‐driven precision dosing program.
UTMB set out to address the fact they were not providing enough clinical services based on genomics. “It was not standard practice for the pharmacy to be involved and we knew it was time for a new approach in order to become a precision medical organization,” Akeem Bale, Pharmacy Manager, UMTB PharmD, MS, MBA, BCPS, BCSCP. “The first stage is to focus on providing a pharmacokinetic service for our providers with aminoglycoside and vancomycin AUC/MIC models. The degree of precision these provide is really extraordinary and only the beginning steps for our therapeutic drug modeling initiative.”
In the last decade, genetic biomarker development has facilitated progress in everything from clinical trial design, to precision dosing with unprecedented advances in targeted therapies, immunotherapy and decreased toxicity levels. The dosing of therapeutics must follow this same protocol to improve patient care.
“DoseMe is very excited to partner with UTMB on their long-term, precision strategy that expands well beyond antibiotic models and into oncology, pediatrics and much more,” stated Paul Edwards, CEO of DoseMe. “With over 1.3 million dose calculations made to date, DoseMeRx is the most established Bayesian Dosing Platform on the market, and the feedback from customers like UTMB continues to improve our broad suite of dosing models.”
The only HITRUST CSF certified dosing platform, Doseme is approved by web and IT teams.
UTMB chose to integrate DoseMeRx into the EPIC Electronic Health Records (EHR) for real-time data. It allows agents to quickly and efficiently access and manage critical information, including viewing patient history and medication details, previous contacts, and altering future appointments.
This gives the whole picture of a patient at a glance with historical, current dose and future predicted dosing outcomes. The interface gives customers the ability to edit the data when needed for more accurate, up-to-date patient data.
For the full list of current models for precision dosing, visit https://doseme-rx.com/why-dosemerx/drug-packages.
Totally agree very annoying tbh….100% would put any new investors coming on board imo. Guess that’s the point…..
Irrespective of people’s opinion there is definitely value down here at these prices